Denali Therapeutics Inc. (DNLI)

Over the past six months, Denali's stock has been impacted by several key events. The FDA approval of AVLAYAH™ for Hunter Syndrome likely had a positive impact. Q1 2026 financial results showed a narrower-than-expected loss, but shares fell. Takeda's termination of the collaboration for DNL593 introduced uncertainty. Q4 and full-year 2025 financial results highlighted launch readiness for tividenofusp alfa. The clinical hold was lifted for DNL952, and a Phase 1b study was initiated for DNL628. Denali's stock increased by 18.8% between the beginning of 2026 and May 9, 2026.

The demand for Denali Therapeutics' products and services is generally not subject to traditional seasonal fluctuations. The need for these therapies is driven by disease prevalence and progression, rather than cyclical patterns. The company's revenue generation is tied to regulatory approvals, successful clinical trials, and commercialization efforts.

Denali Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases. The company operates within the Biotechnology & Medical Research sector, utilizing its TransportVehicle™ (TV) platform to deliver treatments across the blood-brain barrier (BBB). Denali's pipeline includes small molecule and biotherapeutic medicines, with candidates in clinical development across various indications, including AVLAYAH™ for Hunter syndrome, BIIB122/DNL151 for Parkinson's disease, DNL343 for ALS, SAR443820/DNL788 for multiple sclerosis, TAK-594/DNL593 for frontotemporal dementia, DNL126 for MPS IIIA, DNL952 for Pompe disease, DNL628 for Alzheimer's disease, DNL921 for Alzheimer's disease, DNL111 for Parkinson's and Gaucher diseases, DNL622 for MPS I, and DNL422 for Parkinson's disease.

Denali Therapeutics, Inc. is headquartered in South San Francisco, California, United States. The company also has locations in Salt Lake City, Utah, and Zurich, Switzerland.

Denali Therapeutics emphasizes a strong commitment to patient communities, actively collaborating with individuals and families to incorporate their feedback into all stages of drug discovery and development. The recent U.S. FDA approval of AVLAYAH™ for Hunter Syndrome enhances Denali's reputation as a pioneer in biotherapeutics. No specific events negatively impacting Denali Therapeutics' brand reputation in the past year were found.

Denali Therapeutics' ownership is heavily influenced by major institutional investors, who collectively hold over 90% of the company's stock. BlackRock, Inc. is the largest institutional shareholder. Founder and insider ownership represents a smaller portion of the company's shares, with Robert Nelsen being a key individual shareholder and Ryan J. Watts and Alex Schuth retaining stakes as insiders.